The US generics business is under severe structural pricing pressure, with no near-term catalyst for reversal. Watch for further erosion in upcoming quarters and the pace of new product launches (79 ANDAs pending, 24 first-to-file). The semaglutide quality issue may signal broader manufacturing risk; monitor FDA inspection outcomes at the Biologics Hyderabad facility (7 observations in June 2026). Non-US growth is strong but insufficient to offset US headwinds. The new auditor appointment (Deloitte) is a governance change worth noting but not immediately material.
Drug in focus
RDY drug pipeline →semaglutide
◆ Mixed Named in this 6-K- Impact
- Phase
- Approved - Generic
- Time to market
- Already launched in India (March 2026) and Canada (May 2026), but supply halted until ~October 2026 due to API impurity. US market entry not expected until patent exclusivity ends ~2031-2032.
- Next catalyst
- None dated
What to watchWatch for Dr. Reddy's API remediation progress and the late-October 2026 supply restart timeline. The supply halt halved the FY27 production target from 12M to 6-7M pens and erased ~$678M in market cap. Any update on resolving the impurity issue, regulatory findings, or competitive dynamics (Apotex, USV) could move shares. US market entry (2031-2032 patent expiry) is the long-term prize but too distant to trade on now.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 22 $11.38entry
- T+1 · 4mo ago +3.69%α +4.93% · $11.80
- T+5 · 4mo ago +3.34%α +5.74% · $11.76
- T+20 · 3mo ago +6.41%α +3.52% · $12.11
- T+60 · 5w ago +13.36%α +10.09% · $12.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dr. Reddy's Q1 FY2027 results were sharply below prior year: revenue fell 6% YoY to Rs.80,705M, operating profit collapsed 78% to Rs.3,784M, and EPS dropped 69% to Rs.5.32. The US generics business was the primary drag, with North America revenue down 35% (41% in USD) due to price erosion and volume declines. Gross margin contracted 10.4pp to 46.5%, further pressured by a Rs.2,397M semaglutide inventory write-down. Growth in India (+17%), Emerging Markets (+31%), and Russia (+28%) partially offset the US decline but could not prevent a 69% profit plunge.
Key Facts
- Revenue decreased 6% YoY to Rs.80,705M (Q1 FY2026: Rs.85,452M)
- North America (US+Canada) revenue fell 35% to Rs.22,048M; in USD terms down 41%
- Gross profit margin collapsed from 56.9% to 46.5%
- Operating profit (results from operating activities) down 78% to Rs.3,784M
- Net profit attributable to parent down 69% to Rs.4,435M; basic EPS Rs.5.32 vs Rs.17.04
- Rs.2,397M provision for semaglutide inventory write-down due to API quality issue
- SG&A expenses rose 12% YoY to Rs.28,820M (35.7% of revenue vs 30.0%)
- India revenue +17%, Emerging Markets +31%, Russia +28% (INR terms)
- Board appointed Deloitte Haskins & Sells as new independent auditor
- Proposed dividend of Rs.8 per share (subject to shareholder approval)
Financial Impact
Revenue decline of ~Rs.4,747M ($50M) and net profit decline of ~Rs.9,743M ($103M) YoY; gross margin compression of 10.4pp represents ~Rs.11,087M in lost gross profit
Risk Factors
- Continued US generic price erosion and volume declines
- FDA regulatory actions or warning letters following June 2026 inspection
- Additional costs or liabilities from semaglutide quality issue
- Geopolitical risks in Russia/Ukraine (28% of revenue from Russia)
- Ranitidine litigation settlement costs (Illinois cases pending)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (RDY), Batch item 1 | 0001575872-26-000522 |
| Exhibit: ex991_1.htm | 0001575872-26-000522 |
| Document: 0001575872-26-000522-index-headers.html | 0001575872-26-000522 |
| Document: 0001575872-26-000522-index.html | 0001575872-26-000522 |
| Document: 0001575872-26-000522.txt | 0001575872-26-000522 |
| 6-K Filing (RDY), Batch item 6 | 0001575872-26-000522 |
| Exhibit: ex991_1.htm | 0001575872-26-000522 |
| Document: 0001575872-26-000522-index-headers.html | 0001575872-26-000522 |
| Document: 0001575872-26-000522-index.html | 0001575872-26-000522 |
| Document: 0001575872-26-000522.txt | 0001575872-26-000522 |
Track record
73 reports on RDY
7 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 11 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers